Last reviewed · How we verify
Atenolol Pill
Atenolol is a beta-1 selective adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of norepinephrine and epinephrine on the heart.
Atenolol is a beta-1 selective adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of norepinephrine and epinephrine on the heart. Used for Hypertension, Angina pectoris, Acute myocardial infarction.
At a glance
| Generic name | Atenolol Pill |
|---|---|
| Sponsor | Tartu University Hospital |
| Drug class | Beta-1 selective adrenergic antagonist (beta-blocker) |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Atenolol selectively blocks beta-1 adrenergic receptors on cardiac tissue, decreasing heart contractility and heart rate. This reduces cardiac oxygen demand and lowers blood pressure. The drug is cardioselective at therapeutic doses, meaning it preferentially targets cardiac beta-1 receptors over beta-2 receptors in the lungs and vasculature.
Approved indications
- Hypertension
- Angina pectoris
- Acute myocardial infarction
- Atrial fibrillation for rate control
Common side effects
- Fatigue
- Dizziness
- Bradycardia
- Hypotension
- Cold extremities
- Bronchospasm (in susceptible patients)
- Sexual dysfunction
Key clinical trials
- Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF) (PHASE4)
- Comparison Between Atenolol,Propnalol and Ivabradine (NA)
- Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial (PHASE3)
- The Effect of Nitrendipine/Atenolol Combination on Blood Pressure Variability. (PHASE4)
- Single Pill to Avert Cardiovascular Events (PHASE3)
- The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma (PHASE4)
- Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism (EARLY_PHASE1)
- The Impact of Heart Rate on Central Blood Pressure in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atenolol Pill CI brief — competitive landscape report
- Atenolol Pill updates RSS · CI watch RSS
- Tartu University Hospital portfolio CI